A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination With Methotrexate Therapy, in Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2017
At a glance
- Drugs GSK 3196165 (Primary) ; Folic acid; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 19 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 13 Dec 2017.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated